

Leonard Pinchuk, Ph.D., D.Sc. – serial inventor of transformative biomaterial technologies benefitting hundreds of millions of patients globally

Recipient of the 2017 BioMed SA Award for Innovation in Healthcare & Bioscience



Leonard Pinchuk, Ph.D., D.Sc.
with his InnFocus MicroShunt® which prevents the progression of vision loss due to glaucoma.

Selection committee rationale:

- World-renowned biomaterials scientist, chemist, engineer and lead inventor of disruptive biomedical innovations including:
 - World's first commercially successful angioplasty balloon catheter
 - TAXUS® - World's most successful drug-eluting coronary stent
 - InnFocus MicroShunt® - Novel device to stop vision loss from glaucoma
 - Two biomaterials used for implant applications
- More than 120 patents impacting hundreds of millions of lives
- Elected member of the highly esteemed National Academy of Engineering
- Founder of Innovia LLC, which has incubated and spun off eight biomedical technologies

Dr. Leonard Pinchuk of Miami, Florida, is a serial innovator and entrepreneur with more than 120 issued U.S. patents and 90 publications, and the founder or co-founder of 10 biomedical companies. His major accomplishments include invention of the world's first commercially successful and most widely used angioplasty balloon catheters, the helical wire stent, the modular stent-graft, the market-leading drug-eluting stent (TAXUS®), two biostable implantable biomaterials (polycarbonate urethane and poly(styrene-*block*-isobutylene-*block*-styrene) or SIBS), a novel glaucoma bypass shunt (InnFocus MicroShunt®) and next-generation intraocular lens material.

Dr. Pinchuk began his career in 1983 at Cordis Corporation and left in 1987 to co-found Corvita Corporation (angioplasty catheters, vascular grafts, stents, stent-grafts), which went public on the NASDAQ in 1994, was acquired by Pfizer, Inc. in 1996, and was then sold to Boston Scientific Corporation in 1998.

In 2002, Dr. Pinchuk founded Innovia LLC, which went on to incubate eight companies working in the fields of intraocular lenses, glaucoma shunts, radiation oncology catheters, urinary catheters, gene therapy and futuristic biomaterials. One of the Innovia spin-offs, InnFocus, Inc., developed a novel medical device to treat glaucoma and was acquired by Santen Pharmaceutical Co., Ltd. (Japan) in 2016. Dr. Pinchuk currently serves as the Chief Scientific Officer at InnFocus. He continues to serve as Innovia's CEO and President and also enjoys an appointment as Research Professor of Biomedical Engineering at the University of Miami.

Dr. Pinchuk received a B.Sc. in Chemistry from McGill University (1976), a Ph.D. interdisciplinary in Engineering and Chemistry from the University of Miami (1984) and an honorary Doctor of Science degree from McGill University (2005). He was inducted into the American Institute for Medical and Biological Engineering (AIMBE) in 2007 and the National Academy of Engineering in 2012 and was awarded the 2017 Society for Biomaterials Technology, Innovation and Development Award.